Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H23NO |
Molecular Weight | 257.3706 |
Optical Activity | ( + ) |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H]1[C@@H]2CC3=C(C=C(O)C=C3)[C@@]1(C)CCN2CC=C
InChI
InChIKey=LGQCVMYAEFTEFN-DQYPLSBCSA-N
InChI=1S/C17H23NO/c1-4-8-18-9-7-17(3)12(2)16(18)10-13-5-6-14(19)11-15(13)17/h4-6,11-12,16,19H,1,7-10H2,2-3H3/t12-,16+,17+/m1/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/17200725Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/7957624 |
https://www.ncbi.nlm.nih.gov/pubmed/23139844
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17200725
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/7957624 |
https://www.ncbi.nlm.nih.gov/pubmed/23139844
(+)-SKF-10,047 is a sigma-opioid receptor agonist. (+)-SKF-10,047 is distinct from its (-)-enantiomer in binding pattern and associated behavioural effects. (+)-SKF-10,047 stress-induced motor suppression, while its (-)-optical isomer was inactive. Besides activation of sigma-1 receptor, (+)-SKF-10,047 is inhibitor of Na(V)1.2 and Na(V)1.4 channels.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7957624
Curator's Comment: Known to be CNS penetrant in rats. Human data not available.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/5970903
Curator's Comment: Now GlaxoSmithKline
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL287 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2986989 |
18.0 nM [Ki] | ||
Target ID: CHEMBL4187 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23139844 |
140.0 µM [IC50] | ||
Target ID: CHEMBL2072 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23139844 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9042587 |
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9042587
To evaluate effect of (+)-SKF-10,047 on conditioned fear stress, the drug was administered subcutaneously at 20 min before motility was measured in the test trial. (+)-SKF-10,047 (3 and 6 mg/kg) dose-dependently attenuated the conditioned fear stress.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17200725
Inhibition of sigma opioid receptor from guinea brains was studied using radioligand binding assay, with 3H-SKF10047 used as a radioligand. (+)-SKF-10,047 displaces [3H]-(+)*SKF10047 with Ki of 18 nM
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID90207344
Created by
admin on Sat Dec 16 17:36:14 GMT 2023 , Edited by admin on Sat Dec 16 17:36:14 GMT 2023
|
PRIMARY | |||
|
58640-82-7
Created by
admin on Sat Dec 16 17:36:14 GMT 2023 , Edited by admin on Sat Dec 16 17:36:14 GMT 2023
|
PRIMARY | |||
|
YR49MN7Q8G
Created by
admin on Sat Dec 16 17:36:14 GMT 2023 , Edited by admin on Sat Dec 16 17:36:14 GMT 2023
|
PRIMARY | |||
|
3036222
Created by
admin on Sat Dec 16 17:36:14 GMT 2023 , Edited by admin on Sat Dec 16 17:36:14 GMT 2023
|
PRIMARY |
SALT/SOLVATE (PARENT)
SUBSTANCE RECORD